{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:46:20Z","timestamp":1782823580752,"version":"3.54.5"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Urate and oxypurinol, allopurinol\u2019s active metabolite, are predominantly eliminated by the kidneys. Therefore, optimising allopurinol dosing in patients on dialysis is challenging. This review explores allopurinol dosing practices, oxypurinol pharmacokinetics, and effectiveness in gout patients receiving haemodialysis or peritoneal dialysis (PD). Five databases and grey literature were searched. Studies on gout patients on allopurinol, receiving dialysis, and reporting dosing, pharmacokinetics, or effectiveness (reduction in urate and\/or gout flares) were included. Abstract, full text screening and data extraction were done by two authors. Studies were grouped by dialysis modality. Eighteen studies were identified including 390 patients, most (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009274, 70%) on haemodialysis with allopurinol administered after dialysis. The peritoneal dialytic clearance of oxypurinol (3.14\u00a0mL\/min,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) and urate (2.7\u20134\u00a0mL\/min,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200925) was similar. The haemodialytic clearance was 78\u2013137\u00a0mL\/min for oxypurinol (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921) and 80\u2013165\u00a0mL\/min for urate (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919). Allopurinol doses were higher in haemodialysis (100\u2013600\u00a0mg\/day) than PD (110\u2013125\u00a0mg\/day). Haemodialysis sessions decreased oxypurinol and urate concentrations by 39\u201357% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200930) and 56\u201371% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096), respectively. Over time (1\u2013230\u00a0days), urate concentrations in haemodialysis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200985) reduced by 14\u201341%. Target serum urate (&lt;\u20090.36\u00a0mmol\/L) was achieved in 61% (20\/33) and 47% (13\/28) of haemodialysis and PD patients, respectively. Gout flares decreased from 2 to 0.1 attacks\/year in patients receiving dialysis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200979). Oxypurinol and urate clearance by haemodialysis was higher than PD, necessitating higher doses of allopurinol. POST dialysis allopurinol doses titrated to target urate are suggested. Future studies considering the impact of dialysis modality on allopurinol dose requirements are needed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s40620-025-02269-7","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:49:59Z","timestamp":1743119399000},"page":"859-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-9555","authenticated-orcid":false,"given":"Noha A.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6615-4998","authenticated-orcid":false,"given":"Michael A.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-9252","authenticated-orcid":false,"given":"Daniel F. B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7648-007X","authenticated-orcid":false,"given":"Kamal","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-0708","authenticated-orcid":false,"given":"Surjit","family":"Tarafdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5128-7115","authenticated-orcid":false,"given":"Ronald L.","family":"Castelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2269_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50:S11\u2013S16. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.008","journal-title":"Semin Arthritis Rheum"},{"key":"2269_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","volume":"392","author":"HH Kyu","year":"2018","unstructured":"Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H et al (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1859\u20131922. https:\/\/doi.org\/10.1016\/S0140-6736(18)32335-3","journal-title":"Lancet"},{"key":"2269_CR3","first-page":"759","volume":"98","author":"N Schlesinger","year":"2007","unstructured":"Schlesinger N (2007) Diagnosis of gout. Minerva Med 98:759\u2013767","journal-title":"Minerva Med"},{"key":"2269_CR4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1136\/ard.2010.128454","volume":"69","author":"N Schlesinger","year":"2010","unstructured":"Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907\u20131912. https:\/\/doi.org\/10.1136\/ard.2010.128454","journal-title":"Ann Rheum Dis"},{"key":"2269_CR5","unstructured":"TherapeuticGuidelines (2021) Gout. https:\/\/tgldcdp.tg.org.au\/viewTopic?etgAccess=true&guidelinePage=Rheumatology&topicfile=gout&guidelinename=Rheumatology&sectionId=toc_d1e232#toc_d1e232. Accessed 28 June 2021"},{"key":"2269_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T (2017) Management of gout and hyperuricemia in CKD. Am J Kidney Dis 70:422\u2013439. https:\/\/doi.org\/10.1053\/j.ajkd.2017.01.055","journal-title":"Am J Kidney Dis"},{"key":"2269_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46:623\u2013644. https:\/\/doi.org\/10.2165\/00003088-200746080-00001","journal-title":"Clin Pharmacokinet"},{"key":"2269_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356. https:\/\/doi.org\/10.1016\/0002-9343(84)90743-5","journal-title":"Am J Med"},{"key":"2269_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W et al (2017) The British Society for Rheumatology Guideline for the management of gout. Rheumatology (Oxford) 56:e1\u2013e20. https:\/\/doi.org\/10.1093\/rheumatology\/kex156","journal-title":"Rheumatology (Oxford)"},{"key":"2269_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan E (2012) Reduced glomerular function and prevalence of gout: NHANES 2009\u201310. PLoS ONE 7:e50046. https:\/\/doi.org\/10.1371\/journal.pone.0050046","journal-title":"PLoS ONE"},{"key":"2269_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210487","volume":"14","author":"E Mohammed","year":"2019","unstructured":"Mohammed E, Browne LD, Kumar AUA, Adeeb F, Fraser AD, Stack AG (2019) Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: a national study. PLoS ONE 14:e0210487. https:\/\/doi.org\/10.1371\/journal.pone.0210487","journal-title":"PLoS ONE"},{"key":"2269_CR12","unstructured":"KDIGO (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https:\/\/kdigo.org\/wp-content\/uploads\/2024\/03\/KDIGO-2024-CKD-Guideline.pdf. Accessed 25 Mar 2024"},{"key":"2269_CR13","doi-asserted-by":"publisher","unstructured":"Day RO, Kannangara DR, Hayes JM, Furlong T (2012) Successful use of allopurinol in a patient on dialysis. BMJ Case Rep 2012:bcr0220125814. https:\/\/doi.org\/10.1136\/bcr.02.2012.5814","DOI":"10.1136\/bcr.02.2012.5814"},{"key":"2269_CR14","unstructured":"UpToDate (2023) Allopurinol: drug information. https:\/\/www.uptodate.com\/contents\/allopurinol-drug-information?source=mostViewed_widget. Accessed 28 Nov 2023."},{"key":"2269_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/sdi.12735","volume":"32","author":"M Murea","year":"2019","unstructured":"Murea M, Tucker BM (2019) The physiology of uric acid and the impact of end-stage kidney disease and dialysis. Semin Dial 32:47\u201357. https:\/\/doi.org\/10.1111\/sdi.12735","journal-title":"Semin Dial"},{"key":"2269_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"2269_CR17","doi-asserted-by":"publisher","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, McInerney P et al (2021) Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. https:\/\/doi.org\/10.11124\/JBIES-20-00167","DOI":"10.11124\/JBIES-20-00167"},{"key":"2269_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"key":"2269_CR19","unstructured":"Rohatgi A (2022) WebPlotDigitizer. https:\/\/automeris.io\/WebPlotDigitizer. Accessed 2 Mar 2022"},{"key":"2269_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.12793\/tcp.2016.24.4.153","volume":"24","author":"AJ Atkinson","year":"2016","unstructured":"Atkinson AJ (2016) Pitfalls in the calculation of hemodialysis clearance and in the assessment of dialysis efficacy. Transl Clin Pharmacol 24:153\u2013156","journal-title":"Transl Clin Pharmacol"},{"key":"2269_CR21","unstructured":"Fick A (1870) Ueber die Messung des Blutquantums in den Herzventrikeln"},{"issue":"7","key":"2269_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/imj.14163","volume":"49","author":"E Yeo","year":"2019","unstructured":"Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK (2019) Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. Intern Med J 49(7):838\u2013842. https:\/\/doi.org\/10.1111\/imj.14163","journal-title":"Intern Med J"},{"key":"2269_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/nep.14306","volume":"29","author":"LC Wilson","year":"2024","unstructured":"Wilson LC, Ward J, Wright DFB, Green SC, Stocker SL, Putt TL, Schollum JBW et al (2024) The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout. Nephrology (Carlton) 29:547\u2013550. https:\/\/doi.org\/10.1111\/nep.14306","journal-title":"Nephrology (Carlton)"},{"issue":"8","key":"2269_CR24","doi-asserted-by":"publisher","first-page":"E362","DOI":"10.1097\/RHU.0000000000001438","volume":"27","author":"MD Arenas","year":"2021","unstructured":"Arenas MD, Soriano R, Andres M, Pascual E (2021) Serum urate levels of hemodialyzed renal patients revisited. J Clin Rheumatol 27(8):E362\u2013E366. https:\/\/doi.org\/10.1097\/RHU.0000000000001438","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"2269_CR25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/15257770.2021.1934482","volume":"40","author":"C Diez-Lopez","year":"2021","unstructured":"Diez-Lopez C, Perez-Contreras J, Andres M (2021) Urate levels and clearance in renal patients under peritoneal dialysis. Nucleosides Nucleotides Nucleic Acids 40(7):720\u2013731. https:\/\/doi.org\/10.1080\/15257770.2021.1934482","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2269_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/0886022X.2020.1835674","volume":"42","author":"B Rohn","year":"2020","unstructured":"Rohn B, Jansing W, Seibert FS, Pfab T, Cinkilic O, Pasfall J, Schmidt S et al (2020) Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients. Ren Fail 42:1067\u20131075. https:\/\/doi.org\/10.1080\/0886022X.2020.1835674","journal-title":"Ren Fail"},{"key":"2269_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-4615-9140-5_43","volume":"122A","author":"GB Elion","year":"1980","unstructured":"Elion GB, Benezra FM, Beardmore TD, Kelley WN (1980) Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol 122A:263\u2013267. https:\/\/doi.org\/10.1007\/978-1-4615-9140-5_43","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2269_CR28","first-page":"385","volume":"9","author":"B Shelmadine","year":"2009","unstructured":"Shelmadine B, Bowden RG, Wilson RL, Beavers D, Hartman J (2009) The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. Anadolu Kardiyol Derg 9(5):385\u2013389","journal-title":"Anadolu Kardiyol Derg"},{"key":"2269_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-4615-5381-6_10","volume":"431","author":"S Reiter","year":"1998","unstructured":"Reiter S, Engelleiter R, Proske H, Muller A, Van Der Woude FJ, Duley JA, Simmonds HA (1998) Severe debilitating polyarticular gout and terminal renal failure in an allopurinol \u201cnon-responder.\u201d Adv Exp Med Biol 431:51\u201355. https:\/\/doi.org\/10.1007\/978-1-4615-5381-6_10","journal-title":"Adv Exp Med Biol"},{"key":"2269_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","volume":"66","author":"KDOQI","year":"2015","unstructured":"KDOQI (2015) KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66:884\u2013930. https:\/\/doi.org\/10.1053\/j.ajkd.2015.07.015","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"2269_CR31","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1053\/j.ajkd.2006.04.006","volume":"48","author":"KDOQI","year":"2006","unstructured":"KDOQI (2006) Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 48(Suppl 1):S98-129. https:\/\/doi.org\/10.1053\/j.ajkd.2006.04.006","journal-title":"Am J Kidney Dis"},{"key":"2269_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ekir.2020.10.025","volume":"6","author":"E Rutherford","year":"2021","unstructured":"Rutherford E, Ireland S, Mangion K, Stewart GA, MacGregor MS, Roditi G, Woodward R et al (2021) A randomized, controlled trial of the effect of allopurinol on left ventricular mass index in hemodialysis patients. Kidney Int Rep 6:146\u2013155. https:\/\/doi.org\/10.1016\/j.ekir.2020.10.025","journal-title":"Kidney Int Rep"},{"key":"2269_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00228-016-2133-y","volume":"73","author":"D Wright","year":"2017","unstructured":"Wright D, Doogue M, Barclay M, Chapman P, Cross N, Irvine J, Stamp L (2017) A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol 73:71\u201378. https:\/\/doi.org\/10.1007\/s00228-016-2133-y","journal-title":"Eur J Clin Pharmacol"},{"key":"2269_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000076857","volume":"22","author":"SC Hsu","year":"2004","unstructured":"Hsu SC, Lee YY, Wang MC, Liu HL, Cheng MF, Huang JJ (2004) Diffuse calcinosis and intradermal tophi in a uremic patient: effect of low-calcium hemodialysis and mechanism of hypercalcemia. Blood Purif 22:224\u2013228. https:\/\/doi.org\/10.1159\/000076857","journal-title":"Blood Purif"},{"key":"2269_CR35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.14842\/jpnjnephrol1959.35.783","volume":"35","author":"O Matsuda","year":"1993","unstructured":"Matsuda O, Otsuka M, Yamada T, Tomita K, Marumo F (1993) Therapeutic effect of hemodialysis on gouty arthritis and tophi in 2 patients with chronic renal failure. Nihon Jinzo Gakkai Shi. 35:783\u2013789. https:\/\/doi.org\/10.14842\/jpnjnephrol1959.35.783","journal-title":"Nihon Jinzo Gakkai Shi."},{"key":"2269_CR36","first-page":"618","volume":"54","author":"WJ Johnson","year":"1979","unstructured":"Johnson WJ, O\u2019Duffy JD (1979) Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol. Mayo Clin Proc 54:618\u2013620","journal-title":"Mayo Clin Proc"},{"key":"2269_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00002480-196504000-00047","volume":"11","author":"CP Hayes Jr","year":"1965","unstructured":"Hayes CP Jr, Metz EN, Robinson RR, Rundles RW (1965) The use of allopurinol (Hpp) to control hyperuricemia in patients on chronic intermittent hemodialysis. Trans Am Soc Artif Intern Organs 11:247\u2013254","journal-title":"Trans Am Soc Artif Intern Organs"},{"issue":"7","key":"2269_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2169\/internalmedicine.44.706","volume":"44","author":"I Ohno","year":"2005","unstructured":"Ohno I, Ichida K, Okabe H, Hikita M, Uetake D, Kimura H, Saikawa H et al (2005) Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern Med 44(7):706\u2013709. https:\/\/doi.org\/10.2169\/internalmedicine.44.706","journal-title":"Intern Med"},{"key":"2269_CR39","unstructured":"TGA (2023) Australian Product Information\u2014Zyloprim (Allopurinol). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=PI&q=Zyloprim&r=\/. Accessed 8 Dec 2023"},{"key":"2269_CR40","unstructured":"TGA (2023) Australian Product Information\u2014Allosig (Allopurinol). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=PI&q=Allosig&r=\/. Accessed 8 Dec 2023"},{"key":"2269_CR41","unstructured":"TGA (2023) Australian Product Information Progout\u00ae (Allopurinol) Tablets. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=&q=progout&r=\/. Accessed Dec 8th 2023."},{"key":"2269_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/membranes11100767","author":"N Said","year":"2021","unstructured":"Said N, Lau WJ, Ho YC, Lim SK, Zainol Abidin MN, Ismail AF (2021) A review of commercial developments and recent laboratory research of dialyzers and membranes for hemodialysis application. Membranes (Basel). https:\/\/doi.org\/10.3390\/membranes11100767","journal-title":"Membranes (Basel)"},{"key":"2269_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1053\/ajkd.2000.8985","volume":"36","author":"NA Hoenich","year":"2000","unstructured":"Hoenich NA, Stamp S (2000) Clinical performance of a new high-flux synthetic membrane. Am J Kidney Dis 36:345\u2013352. https:\/\/doi.org\/10.1053\/ajkd.2000.8985","journal-title":"Am J Kidney Dis"},{"key":"2269_CR44","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.05150418","author":"DM Roberts","year":"2018","unstructured":"Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN (2018) Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/cjn.05150418","journal-title":"Clin J Am Soc Nephrol"},{"key":"2269_CR45","unstructured":"DRUGbankOnline (2023) Oxypurinol. https:\/\/go.drugbank.com\/drugs\/DB05262. Accessed 27 June 2023"},{"key":"2269_CR46","unstructured":"DRUGbankOnline (2020) Uric acid. https:\/\/go.drugbank.com\/drugs\/DB08844. Accessed 27 June 2020"},{"key":"2269_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/0471140856.txa03hs10","author":"SM Andrew","year":"2002","unstructured":"Andrew SM, Titus JA, Zumstein L (2002) Dialysis and concentration of protein solutions. Curr Protoc Toxicol. https:\/\/doi.org\/10.1002\/0471140856.txa03hs10","journal-title":"Curr Protoc Toxicol"},{"key":"2269_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/pds.5127","volume":"30","author":"R Koto","year":"2021","unstructured":"Koto R, Nakajima A, Horiuchi H, Yamanaka H (2021) Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: a retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiol Drug Saf 30:157\u2013168. https:\/\/doi.org\/10.1002\/pds.5127","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2269_CR49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14397595.2020.1800557","volume":"31","author":"JEC Quilisadio","year":"2021","unstructured":"Quilisadio JEC, Salido EO, Penserga EG (2021) Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines. Mod Rheumatol 31:755\u2013761. https:\/\/doi.org\/10.1080\/14397595.2020.1800557","journal-title":"Mod Rheumatol"},{"key":"2269_CR50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3899\/jrheum.190522","volume":"47","author":"JA Singh","year":"2020","unstructured":"Singh JA, Yang S, Saag KG (2020) Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US veterans affairs gout cohort. J Rheumatol 47:449. https:\/\/doi.org\/10.3899\/jrheum.190522","journal-title":"J Rheumatol"},{"key":"2269_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1471-2474-13-174","volume":"13","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ (2012) Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord 13:174. https:\/\/doi.org\/10.1186\/1471-2474-13-174","journal-title":"BMC Musculoskelet Disord"},{"key":"2269_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/art.42731","volume":"76","author":"LN Helget","year":"2024","unstructured":"Helget LN, O\u2019Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR et al (2024) Determinants of achieving serum urate goal with treat-to-target urate-lowering therapy in gout. Arthritis Rheumatol 76:638\u2013646. https:\/\/doi.org\/10.1002\/art.42731","journal-title":"Arthritis Rheumatol"},{"key":"2269_CR53","first-page":"69","volume":"47","author":"J Mangkala","year":"2022","unstructured":"Mangkala J (2022) Treat-to-target of gouty arthritis at Rak-Kor Clinic Nongkhai Hospital. J DMS 47:69\u201377","journal-title":"J DMS"},{"key":"2269_CR54","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/bcp.13798","volume":"85","author":"LK Stamp","year":"2019","unstructured":"Stamp LK, Wright DFB, Dalbeth N (2019) Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate! Br J Clin Pharmacol 85:1378\u20131379. https:\/\/doi.org\/10.1111\/bcp.13798","journal-title":"Br J Clin Pharmacol"},{"key":"2269_CR55","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","volume":"18","author":"HK Choi","year":"2022","unstructured":"Choi HK, Zhang Y, Dalbeth N (2022) When underlying biology threatens the randomization principle \u2014 initial gout flares of urate-lowering therapy. Nat Rev Rheumatol 18:543\u2013549. https:\/\/doi.org\/10.1038\/s41584-022-00804-5","journal-title":"Nat Rev Rheumatol"},{"key":"2269_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27:585\u2013591. https:\/\/doi.org\/10.1080\/15257770802136032","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"2","key":"2269_CR57","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s13730-012-0025-2","volume":"1","author":"N Iwata","year":"2012","unstructured":"Iwata N, Maeda H, Yoshimura J, Sakai S (2012) Urgent hemodialysis induced an acute gout attack in a patient with multiple tophi: report of a rare case. CEN Case Rep 1(2):130\u2013131. https:\/\/doi.org\/10.1007\/s13730-012-0025-2","journal-title":"CEN Case Rep"},{"key":"2269_CR58","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/jcm11092468","volume":"11","author":"Y Lee","year":"2022","unstructured":"Lee Y, Hwang J, Desai SH, Li X, Jenkins C, Kopp JB, Winkler CA et al (2022) Efficacy of xanthine oxidase inhibitors in lowering serum uric acid in chronic kidney disease: a systematic review and meta-analysis. J Clin Med 11:2468. https:\/\/doi.org\/10.3390\/jcm11092468","journal-title":"J Clin Med"},{"key":"2269_CR59","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RV Curiel","year":"2012","unstructured":"Curiel RV, Guzman NJ (2012) Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum 42:166\u2013178. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.013","journal-title":"Semin Arthritis Rheum"},{"key":"2269_CR60","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/ki.1994.199","volume":"45","author":"TA Depner","year":"1994","unstructured":"Depner TA (1994) Assessing adequacy of hemodialysis: urea modeling. Kidney Int 45:1522\u20131535. https:\/\/doi.org\/10.1038\/ki.1994.199","journal-title":"Kidney Int"},{"key":"2269_CR61","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22741","volume":"68","author":"H de Lautour","year":"2016","unstructured":"de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA et al (2016) Development of preliminary remission criteria for gout using delphi and 1000minds consensus exercises. Arthritis Care Res (Hoboken) 68:667\u2013672. https:\/\/doi.org\/10.1002\/acr.22741","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2269_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/rap\/rkaa073","volume":"5","author":"H Farquhar","year":"2021","unstructured":"Farquhar H, Vargas-Santos AB, Pisaniello HL, Fisher M, Hill C, Gaffo AL, Stamp LK (2021) Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol Adv Pract 5:13. https:\/\/doi.org\/10.1093\/rap\/rkaa073","journal-title":"Rheumatol Adv Pract"},{"issue":"10","key":"2269_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","volume":"17","author":"LK Stamp","year":"2021","unstructured":"Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, Choi HK et al (2021) Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities. Nat Rev Rheumatol 17(10):633\u2013641. https:\/\/doi.org\/10.1038\/s41584-021-00657-4","journal-title":"Nat Rev Rheumatol"},{"key":"2269_CR64","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/1756-185X.14334","volume":"25","author":"R Alkilany","year":"2022","unstructured":"Alkilany R, Einstadter D, Antonelli M (2022) Urate-lowering therapy for patients with gout on hemodialysis. Int J Rheum Dis 25:769\u2013774. https:\/\/doi.org\/10.1111\/1756-185X.14334","journal-title":"Int J Rheum Dis"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02269-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02269-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02269-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:12Z","timestamp":1777564752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/3\/859\/8457431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2269"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02269-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no declarations of conflict of interest relevant to the article\u2019s content from our researchers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work received no funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ethical approval is not required for scoping reviews (no patient recruitment or primary data collection).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical disclosure"}},{"value":"This scoping review is based on publicly available data and did not involve human participants or animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent\u00a0was not required. (no patient recruitment or primary data collection).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"SS conceived the idea for this review, then developed the inclusion criteria with NK. NK was responsible for development of the search strategy, that was then validated by SS and DW. Title and abstract screening, full text review, and data extraction were done by NK, MS with referral to SS for disagreements. NK drafted the manuscript. All authors contributed to the development of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current review.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}